Compare · HLF vs SCNX
HLF vs SCNX
Side-by-side comparison of Herbalife Ltd. (HLF) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HLF and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- HLF is the larger of the two at $1.35B, about 79.8x SCNX ($17.0M).
- HLF has been more active in the news (8 items in the past 4 weeks vs 4 for SCNX).
- HLF has more recent analyst coverage (14 ratings vs 0 for SCNX).
- Company
- Herbalife Ltd.
- Scienture Holdings Inc.
- Price
- -
- -
- Market cap
- $1.35B
- $17.0M
- 1M return
- +6.11%
- -
- 1Y return
- +40.22%
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 8
- 4
- Recent ratings
- 14
- 0
Herbalife Ltd.
Herbalife Nutrition Ltd. offers nutrition solutions in North America, Mexico, South and Central America, Europe, the Middle East, Africa, and the Asia Pacific. The company provides products in the areas of weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition. It offers weight management products, including meal replacement products, protein shakes, drink mixes, weight loss enhancers, and healthy snacks; targeted nutrition products, which include functional beverages, and dietary and nutritional supplements that contain herbs, vitamins, minerals, and other natural ingredients; outer nutrition products, such as facial skin, body, and hair care products; and energy, sports, and fitness products comprising N-R-G tea and energy drink products. The company also provides literature, promotional, and other materials that include start-up kits, sales tools, and educational materials. It offers its products through independent service providers and sales representatives, as well as through company-operated retail platforms. The company was formerly known as Herbalife Ltd. and changed its name to Herbalife Nutrition Ltd. in April 2018. Herbalife Nutrition Ltd. was founded in 1980 and is headquartered in Los Angeles, California.
Latest HLF
- Amendment: SEC Form SCHEDULE 13G/A filed by Herbalife Ltd.
- Herbalife to Present and Host 1x1 Investor Meetings at Midwest IDEAS Investor Conference on August 26
- Amendment: SEC Form SCHEDULE 13G/A filed by Herbalife Ltd.
- Chief Commercial Officer Lamberti Frank covered exercise/tax liability with 1,710 shares, decreasing direct ownership by 5% to 34,914 units (SEC Form 4) to satisfy withholding obligation
- Herbalife Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Herbalife Ltd.
- Herbalife Reports Second Quarter Net Sales Growth; Marks Fourth Consecutive Quarter of Topline Expansion; Net Sales and Adjusted EBITDA1 Exceed Guidance Excluding FX Headwinds2
- Herbalife Announces Planned CFO Transition
- Herbalife CFO to Participate in Maxim Group “Health, Wellness & Longevity” Virtual Conference on July 22
- Herbalife Named to TIME's List of America’s Best Companies 2026
Latest SCNX
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
- SEC Form 10-Q filed by Scienture Holdings Inc.
- SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
- SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update